Lapatinib, Vinorelbine

DRUG2 trials

Sponsors

GlaxoSmithKline, Central European Cooperative Oncology Group

Conditions

Metastatic Breast CancerNeoplasms, Breast

Phase 2

Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects

TerminatedNCT00709618

GlaxoSmithKlineNeoplasms, Breast

Start: 2008-06-30End: 2012-05-31Updated: 2014-07-14

A Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients

TerminatedNCT01161368

Central European Cooperative Oncology GroupMetastatic Breast Cancer

Start: 2010-09-30End: 2014-05-31Updated: 2015-08-13